background: We investigated the association of vascular endothelial growth factor (VEGF) gene polymorphism with recurrent spontaneous miscarriage (RSM). methods: VEGF 22578C/A, 21154G/A, 2634G/C, +936C/T single nucleotide polymorphisms (SNPs) were assessed in 304 RSM patients, and 371 age-and body mass index-matched control subjects using real-time PCR.
Introduction
Recurrent spontaneous miscarriage (RSM) is a major reproductive problem affecting 1-3% of otherwise healthy women (Sierra and Stephenson, 2006; Brown, 2008) . These authors reported several factors contributing to RSM pathogenesis that included endocrinologic disorders, immune dysfunction, infectious diseases, Mullerian abnormalities, parental chromosomal abnormalities and environmental factors. Despite this, the underlying etiology of RSM remains unknown in most cases, up to 50%, but is likely to be multi-factorial (Christiansen et al., 2008) .
The vascular endothelial growth factor (VEGF) family comprises VEGF (Gospodarovicz et al., 1989; Keck et al., 1989; Leung et al., 1989) , VEGF-B (Olofsson et al., 1996) , VEGF-C , VEGF-D (Orlandini et al., 1996; Yamada et al., 1997) and placenta growth factor (Maglione et al., 1991) . Of these factors, VEGF is a major angiogenic factor, and stimulates the differentiation and proliferation of vascular endothelial cells. VEGF also induces vascular permeability (Keck et al., 1989) , and its expression is stimulated by hypoxia (Ladoux and Frelin, 1993) . VEGF is known to be expressed in the placenta (Sharkey et al., 1993; Vuorela et al., 1997) and in several fetal tissues (Kaipainen et al., 1993) . VEGF acts by binding high-affinity receptors, consisting of three proteintyrosine kinases (VEGFR1, VEGFR2 and VEGFR3) and two non-protein kinase co-receptors (neuropilin-1 and neuropilin-2).
The human VEGF gene is organized in eight exons, separated by seven introns and its coding region spans 14 kb (Houck et al., 1991; Tisher et al., 1991) . The human VEGF gene has been assigned to chromosome 6p21.3 (Vincenti et al., 1996) . Several single nucleotide polymorphisms (SNPs) in the VEGF gene were described (Watson et al., 2000) , some of which are associated with altered production of VEGF, which indicates a regulation of VEGF expression at the transcriptional level (Renner et al., 2000; Watson et al., 2000; Awata et al., 2002; Shahbazi et al., 2002; Krippl et al., 2003; Yang et al., 2003) . Of these, two promoter (21154G/A, 22578C/A), one 5 ′ untranslated region (UTR) (2634G/C) and one 3 ′ -UTR (+936C/T) SNPs have minor alleles correlating with a decreased level of VEGF (Renner et al., 2000; Watson et al., 2000; Awata et al., 2002; Shahbazi et al., 2002; Krippl et al., 2003; Lambrechts et al., 2003; Stevens et al., 2003; Yang et al., 2003) . An association has been described between these SNPs and diseases such as breast cancer, acute renal allograft rejection, prostate cancer (McCarron et al., 2002; Shahbazi et al., 2002; Krippl et al., 2003; Lin et al., 2003) , atherosclerotic cardiovascular disease, pre-eclampsia and pregnancy loss (Papazoglou et al., 2005; Jacobs et al., 2006; Shim et al., 2007) . Our aim was to investigate the allele frequency of those four well characterized VEGF SNPs in Tunisian women with RSM and fertile controls.
Subjects and Methods

Subjects
This was a case -control retrospective study, performed at the Maternity Center of Hô pital Farhat Hached of Sousse, Tunisia. Data collection procedures were the same for patients and control subjects. Patients comprised 304 Tunisian fertile women with three or more RSM of unknown etiology with the same partner. The demographics of the study subjects are summarized in Table I . Exclusion criteria included anatomical abnormalities, previously known systemic disease, endocrine disorders including diabetes mellitus (HbA1c levels were ,6.00 for both patients and controls), previous venous or arterial thrombosis or a family history of thromboembolism. Karyotyping of fetal products was not routinely done due to financial considerations (not covered by public health services). All subjects were negative for coagulation defects, feto-maternal alloimmune thrombocytopenia and antiphospholipid syndrome. Parental chromosomal aberrations and Rhesus incompatibility were ruled out before inclusion in the study. As infection was linked with RSM, all subjects included were confirmed to be free of active infection for the TORCH agents: Toxoplasma gondii, rubella, cytomegalovirus, herpes simplex viruses (HSV-1 and HSV-2), varicella zoster virus and human immunodeficiency virus (HIV-1 and HIV-2) by indirect enzyme-linked immunosorbent assay, i.e. IgM negatives. In total, 136 patients (45.2%) had no live birth, 99 (32.9%) had 1 live birth, 41 (13.6%) had 2 live births and the remaining 28 (8.3%) had 3 live births.
Controls comprised 371 consecutively recruited multi-parous, agematched women who had at least two live births and no spontaneous or induced miscarriages, and did not have a family history of RSM. Patients and controls were all of Arab descent and from the center of Tunisia. In addition, controls were matched to patients according to body mass index (BMI), and a number of risk factors (alcohol consumption, coffee, oral contraceptive use). Smoking habits differed significantly between the two groups ( Table I ). All cases and control subjects were required to sign an informed consent before entering the study that was conducted after all institutional ethics requirements were met. The study protocol was approved by the University of Monastir (Tunisia).
Blood samples were collected from study participants in EDTA tubes and were processed shortly thereafter. Total genomic DNA was extracted from blood leukocyte using the proteinase K/salting out method and was dissolved in sterile nuclease-free water (Miller et al., 1988) .
VEGF gene polymorphisms
′ -UTR, +936C/T (rs3025039) in the 3 ′ -UTR were performed using allelic discrimination TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA). The PCR primers and TaqMan probes were directly available from Applied Biosystem (predesigned assays) and analyses were done according to the manufacturer's protocol on a StepOne plus apparatus (Applied Biosystems), in the genetic department of CHU de Saint Etienne, France. (http://qge.fhcrc.org/hplus). All analyses were conducted under additive genetic effect, using SNPStats software (bioinfo.iconcologia.net/ snpstats/, 23 February 2012, date last accessed). Since we did not genotype the parents of our cohort, it was not possible to establish the true haplotypes from the four SNPs we studied. Therefore, VEGF haplotype estimation was done by the expectation maximization method (HPlus 2.5), where the sum of probability estimates for all possible haplotypes equals 1.0. Haplotype assignment probability estimate was used in determining the individual's contribution to that haplotype where haplotype assignment was uncertain (heterozygous carriers). Logistic regression analysis was performed in order to determine the odds ratios (OR) and 95% confidence intervals (95% CI) associated with the RSM risk, taking the control women as the reference group. This was done first at the univariate, and later at the multivariate levels, after controlling for age and BMI (treated as continuous variables) and smoking (entered as categorical variable). Boneferroni multiple-comparison correction method was employed in calculating the corrected P-value derived from the number of SNPs or haplotypes tested, as per:
Statistical analysis
, where n ¼ number of comparisons. Statistical significance was set at P , 0.05.
Results
Genotype analysis
The distributions of VEGF polymorphisms are shown in Table II .
were in Hardy-Weinberg equilibrium among controls. Higher minor allele frequency (MAF) of 21154G/A (P , 0.001) and +936C/T (P , 0.001), but not 22578C/A (P ¼ 0.55) or 2634G/C (P ¼ 0.87), were seen in patients. Significant differences in the distribution of 21154G/A (P ¼ 0.006) and +936C/T (P ¼ 0.015), but not 22578C/A (P ¼ 0.473) or 2634G/C (P ¼ 1.000) genotypes, were seen in RSM cases compared with control women. Univariate and multivariate logistic regression analysis confirmed the independent association of RSM with 21154G/A under additive (P ¼ 0.002), dominant (P ¼ 0.003) and recessive (P ¼ 0.017) models, and +936C/T under only recessive model (P , 0.001) (Table III) 
VEGF haplotype distribution
Of the possible 16 VEGF haplotypes (22578CA/21154GA/2 634GC/936CT), 9 were found to be common, and were included in subsequent analysis. A significantly lower frequency of C G C C (P ¼ 0.008), and A G G C (P , 0.001) haplotypes, and a higher frequency of C G C T (P ¼ 0.020), and C G G T (P ¼ 0.004) haplotypes were seen in patients (Table IV) . The association of VEGF haplotypes with RSM risk was examined by regression analysis, done first at the univariate, and later at the multivariate levels. Taking the common CGGC haplotype as reference (OR ¼ 1.00), univariate analysis demonstrated the negative association of the CGCC (P ¼ 0. (Table V) .
Discussion
The human placenta is rich in angiogenic factors such as VEGF, which probably play an important role not only in forming placental vessels, but also in maternal vascular adaptation to pregnancy. A role for VEGF in embryonic development and trophoblast vascularization was proposed (Galazios et al., 2009) , and altered expression of VEGF and its receptors were reported in placental and decidual samples from early miscarriages (Vuorela et al., 2000) . Our study is the largest to date that investigated the possible association between four functional VEGF polymorphisms and occurrence of RSM, in 675 women including 304 with RSM. Of the VEGF 22578C/A, 21154G/A, 2634G/C, +936C/T variants studied here, 21154G/A and +936C/T variants were independently associated with the risk of RSM.
Papazoglou first reported an association with RSM using the four polymorphic sites of the VEGF gene used here. For 21154G/A, our results were in agreement with the previous studies on Greek, American and Indian populations (Papazoglou et al., 2005; Coulam and Jeyendran, 2008; Galazios et al., 2009; Aggarwal et al., 2011) . Therefore, the 'low expression' allele (A) at 21154 seems to increase the risk of RSM, possibly through insufficient VEGF level (Brogan et al., 1999; Shahbazi et al., 2002) . Coulam published a cohort of patients with infertility and in vitro fertilization (IVF) implantation failure, finding that a higher proportion of women with IVF failure were homozygous for the 21154 A allele compared with fertile controls (Goodman et al., 2008) . Conversely, the results of those previous studies and our present findings are in contrast to those of Eller et al. (2011) , who found no difference when comparing the proportion of women homozygous for the 21154 A allele between RSM cases and controls, in a small group of American women from Utah (12 versus 10%, P ¼ 0.613). The same study found no difference in the frequency of the 21154 A allele between groups (0.26 versus 0.31, P ¼ 0.296). Another larger study, on the Chinese Han population (including 339 women with RSM and 291 control women), failed to find an association between VEGF 1154G/A polymorphism and susceptibility to RSM (Xing et al., 2011) . These apparent differences may be attributed to the smaller sample size in the study of Eller et al. and to differences in ethnicity in the study from Xing et al. Along these lines, allele A and genotype AA of the VEGF polymorphism 21154G/A are less frequent in Chinese populations. In addition, there is no information in these studies regarding patients and controls matching by BMI, tobacco and alcohol consumption. Additional studies involving larger sample size from other ethnic origins are needed to get a better picture on the role of VEGF in RSM.
The 3 ′ -UTR, +936C/T VEGF polymorphism was linked with altered VEGF expression, and was significantly correlated with the severity of pre-eclampsia (Renner et al., 2000; Shim et al., 2007) . Furthermore, the minor allele of this SNP was associated with lower protein production and increased risk of spontaneous preterm delivery in a Greek population: homozygotes were found to carry the greatest risk with a lesser proportionate risk associated with heterozygosity (Galazios et al., 2009) . Our study identified an increased of this minor allele T in women with RSM (17.6 versus 10.5%, Table II ). Our findings are similar to most studies Lee et al., 2010; Aggarwal et al., 2011) . In another study, the difference did not reach significance, possibly because of the small size of the population (Papazoglou et al., 2005) . Regarding the 22578C/A and the 2634G/C SNPs, no significant association was found in our study between RSM cases and controls. Our results correlated with those of most studies (Papazoglou et al., 2005; Galazios et al., 2009; Lee et al., 2010; Aggarwal et al., 2011) . In fact, only the study of Eller et al. (2011) retrieved opposite results with an association with RSM only for the 22578C/A and 2634G/C SNPs and not for the 21154G/A and +936C/T SNPs. The small size of the population studied in this paper might be responsible for false positive results and association due to chance only.
At the haplotype level, predicted from our results with these four SNPs, extensive diversity was noted, with the majority of variation described by nine common haplotypes. In our population, the C G C C and A G G C, haplotypes were identified as independent protective factors for RSM, after adjusting for age and BMI. In fact, homozygosity for C G C C and A G G C was associated with the lowest RSM risk compared with other haplotype pairs, thus describing a dose-effect relationship.
Our data gave firm support to the association between 'low expression' VEGF polymorphisms and susceptibility to recurrent miscarriages. It adds to a number of studies from several independent groups that support the concept of a human placenta rich in angiogenic factors such as VEGF, which probably play an important role not only in the formation of placental vessels but also in maternal vascular adaptation to pregnancy. Therefore, an insufficient production of VEGF might preclude the development of pregnancy, leading to an increase risk of spontaneous abortion in a polygenic and multi-factorial manner.
